Stock Taper
ZURA
ZURA BIO LIMITED
NASDAQ
$5.72
▼ DOWN 2.22% (-0.13)

KEY STATISTICS

Market Cap$543.39 M
52w High$7.44
52w Low$1.88
Dividend Yield
Frequency
P/E-5.25
Volume1.89M
Shares Out.95.00M

COMPANY

LEADERSHIP

Sandeep C. Kulkarni
CHIEF EXECUTIVE
Sandeep C. Kulkarni

COMPENSATION 2026

Salary$537,751
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$6,659,601

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 21, 2023
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
40

PRICE TARGET

Target High$20.00
Target Low$20.00
Target Median$20.00
Target Consensus$20.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.
NOV
12
THU

PRICE

$5.72 ▼ DOWN 2.22% (−$0.13)
$5.50$5.60$5.70$5.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.72

About Zura Bio Limited

https://zurabio.com ↗

Zura Bio Limited is a San Diego-based clinical-stage biotech developing novel immune and inflammatory therapies, including ZB-168 and Torudokimab, currently in Phase 2 trials.

INDUSTRY

Biotechnology

A PRODUCT ZURA BIO LIMITED IS KNOWN FOR

tibulizumab (ZB-106)
tibulizumab (ZB-106)

Tiburizumab, Zura Bio's lead investigational tetravalent bispecific antibody, targets IL-17A and BAFF to treat autoimmune diseases, currently in Phase 2 trials for systemic sclerosis and hidradenitis suppurativa.

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

DIRECTOR
Eisner Mark
Purchase · 51.0K shares
2026-06-17
DIRECTOR
Schoch Steven J
Purchase · 51.0K shares
2026-06-17
DIRECTOR
Nirula Ajay
Purchase · 51.0K shares
2026-06-17
DIRECTOR
Munshi Amit
Purchase · 51.0K shares
2026-06-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 2
4 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
ASMB$34.07COMPARE
ARCT$15.19COMPARE
ENTA$13.60COMPARE
FHTX$6.00COMPARE
SGMT$10.55COMPARE
PYXS$3.23COMPARE
IMRX$4.99COMPARE
TNYA$0.69COMPARE